This Viewpoint uses the October 2017 mass shooting in Las Vegas to discuss public health imperatives in the US firearm violence epidemic, including long-term treatment of nonfatally injured survivors, management of mental health sequelae for noninjured participants and their communities, and effective responses to commercial stakeholders who benefit from firearm sales at the expense of the public’s health.
This Viewpoint discusses clinical and public health challenges likely to arise from the 2017 change in Centers for Disease Control and Prevention (CDC) recommendations from serologic testing of all Zika-exposed pregnant women regardless of the timing and duration of exposure to testing only those pregnant women with symptoms consistent with infection or with ongoing exposure.
This Viewpoint discusses the president’s recent declaration of a public health emergency in response to the opioid crisis in the United States.
In this Viewpoint, FDA Commissioner Scott Gottlieb and CDER Director Janet Woodcock discuss how the FDA weighs the risks and benefits of opioids and integrates public health and clinical perspectives into decisions about opioid approval, marketing, restrictions, and labeling.
This Viewpoint discusses the rationale for partnerships between law enforcement and public health agencies and suggests strategies to form such partnerships to prevent and respond to violence.
This Viewpoint highlights potential effects of recent finalized changes to the Public Health Service Act.
This Viewpoint discusses potential threats to public health that arise from provisions of the 2016 21st Century Cures Act that allow drug manufacturers to use surrogate measures of safety and that encourage the US Food and Drug Administration to emphasize speed over science in the drug approval process.
This study used data from National Health Expenditure Accounts to estimate US spending on personal health care and public health, according to condition, age and sex group, and type of care.
You currently have no searches saved.